Childhood Cancer & Blood Clots: What Parents Need to Know
"Unveiling the risks and factors of thromboembolism in children with cancer, and how to navigate this critical concern."
The world of pediatric cancer is filled with challenges, and as parents, you want to be armed with as much knowledge as possible. One area that might not be top-of-mind but is crucial to understand is thromboembolism (TE), also known as blood clots. While it might sound like something that primarily affects adults, children with cancer are at an increased risk, and knowing the facts can make a real difference.
Thromboembolism occurs when a blood clot forms in a blood vessel, potentially blocking blood flow and causing serious complications. For children undergoing cancer treatment, the risk can be elevated due to the cancer itself, the treatments they receive, and other related factors. Recognizing the signs and understanding the risk factors are key to ensuring your child receives the best possible care.
This article aims to break down the complexities surrounding thromboembolism in pediatric cancer patients. We will cover what the latest research tells us, what factors increase the risk, and what steps can be taken to protect your child. Knowledge is power, and we are here to empower you with the information you need to navigate this challenging journey.
A Rare but Important Risk
Thromboembolism is rare in healthy children but is an increasing problem among children with underlying conditions such as cancer. One population-based study found that children with cancer had a highly increased relative risk of venous thromboembolism, although the absolute risk remained small at about 1–2 per 1,000 children with cancer per year. The CDC also identifies cancer treatment as a period of particularly high VTE risk.
Treatment Requires Careful Judgment
Pediatric thrombosis research, especially research involving cancer-related thrombosis, remains limited by small studies, although real-world data can provide access to larger and more diverse populations. Providers also lack clear indications, uniform dosing regimens, and strong risk-and-outcome data for thrombolysis in children. Conventional anticoagulant therapy has limitations, while direct oral anticoagulants remain an alternative whose safety and efficacy in children with cancer are still uncertain.
An Evolving Field
The understanding of blood clots in children with cancer has developed gradually alongside advances in pediatric cancer care and thrombosis research. Earlier evidence was limited, so many foundational conclusions came from small studies and clinical experience rather than large pediatric trials. This history helps explain why current practice continues to balance established methods with incomplete evidence.
Why Are Blood Clots a Concern in Pediatric Cancer?
Blood clots can lead to significant health issues, including pain, swelling, and even life-threatening situations if a clot travels to the lungs (pulmonary embolism) or brain (stroke). In children with cancer, these complications can disrupt treatment plans, increase hospital stays, and impact their overall well-being. It's important to note that while the overall incidence of TE is relatively low, the consequences can be severe, making awareness and prevention crucial.
- Chronic Morbidity: Blood clots can lead to long-term health issues.
- Treatment Delays: Thromboembolism can interrupt or modify cancer treatment plans.
- Adverse Effects: Anticoagulation medications used to treat blood clots can have side effects.
- Rare Mortality: In some cases, blood clots can be fatal.
Research Is Still Building
Current reviews of pediatric cancer-associated thrombosis continue to examine how clinicians can identify, prevent, and treat clots more effectively. The evidence base is expanding, but findings remain uneven because pediatric studies are often limited in size and design. As a result, newer approaches must still be evaluated carefully before they can replace established care.
Why Prevention and Treatment Remain Difficult
Thromboembolism can complicate pediatric cancer through the interaction of the malignancy, cancer therapies, and possible inherited thrombophilia. The problem is clinically important even though childhood cancer has cure rates exceeding 80%, because survivors and active-treatment patients may face preventable clot-related complications. These overlapping causes make prevention, early diagnosis, and optimal treatment challenging rather than straightforward.
Comparing Treatment Strategies
Pediatric VTE is uncommon but serious, and management includes several therapeutic options with important challenges. A systematic review is evaluating thrombolysis followed by anticoagulation against anticoagulation alone, reflecting ongoing uncertainty about which children benefit from more intensive treatment. Data from children with cancer-associated VTE suggest that therapeutic anticoagulation is generally safe and effective, but individual treatment decisions remain necessary.
Empowering Parents Through Knowledge
Navigating the complexities of childhood cancer is undoubtedly challenging. Understanding the risk of thromboembolism and its associated factors is a crucial step in advocating for your child's health. By staying informed and working closely with your healthcare team, you can help ensure the best possible outcome for your child.
Care Must Remain Individualized
The available evidence supports treating clot risk in children with cancer as a complex clinical issue rather than a single-condition problem. Decisions may need to account for the cancer, its treatment, bleeding risk, and the limits of pediatric evidence. Families should therefore expect care to involve ongoing assessment and coordination among specialists.
Better Detection and More Targeted Care
The reported increase in childhood thromboembolism over the past decade may reflect both greater diagnostic awareness and the use of more invasive technologies in children with serious underlying conditions. At the same time, the AACR Pediatric Cancer Progress Report 2025 describes progress in molecularly targeted therapies, immunotherapies, and genomic profiling that informs surveillance and treatment decisions. Together, these developments point toward future care that combines earlier recognition of clots with increasingly individualized cancer treatment.
Multiple Forces Shape Clot Risk
Pediatric cancer-associated thrombosis has a multifactorial origin. Risk may reflect pro-coagulant changes caused by the cancer itself, chemotherapy, tumor mass effects, tumor thrombi, or inherited thrombophilia. This combination of biological and treatment-related factors creates a systemic challenge for prevention and management.
Evidence Must Reflect Real Patients
A 2022 study of rivaroxaban reported being the first to examine real-life data in children with cancer-associated thrombosis. Its context is important because children with thrombocytopenia and high bleeding risk had been excluded from previous clinical trials. Real-world evidence can therefore help address questions about treatment in patients who may not fit the populations represented in controlled studies.